Kura Oncology (KURA) Q1 2026 earnings summary

Executive summary

• KOMZIFTI achieved $5.8 million in net product revenue in its first full commercial quarter following FDA approval in November 2025 for relapsed/refractory NPM1-mutated AML, with strong physician adoption, repeat prescriptions, and early switching from other menin inhibitors.

• Over 93% payer coverage was secured, providing favorable access to more than 12 million lives and inclusion in NCCN guidelines.

• The company is advancing multiple phase III programs, with KOMET-017 enrolling ahead of plan and robust clinical data expected over the next 12-24 months.

• Strategic focus is on establishing ziftomenib as a combinable backbone therapy across the AML treatment continuum and expanding into solid tumors with darlifarnib.

• Pipeline includes next-generation menin inhibitors for diabetes and solid tumors.

Financial highlights

• Total revenue for Q1 2026 was $18.3 million, up from $14.1 million in Q1 2025, driven by $5.8 million in new product sales and $12.5 million in collaboration revenue.

• R&D expenses rose to $65.3 million from $56 million, mainly due to expanded clinical trials and phase III enrollment.

• SG&A expenses increased to $31.6 million from $22.8 million, reflecting commercialization investments.

• Net loss widened to $73.3 million from $57.4 million year-over-year.

• Cash, cash equivalents, and short-term investments totaled $580.8 million as of March 31, 2026.

Outlook and guidance

• Collaboration revenue guidance maintained at $45–$55 million for 2026, $90–$110 million for 2027 and 2028.

• Cash and anticipated collaboration payments are expected to fund the AML program through topline Phase 3 KOMET-017 results in 2028.

• Cash runway expected to fund operations into Q4 2027, with additional capital needed for long-term growth.

• Multiple clinical data readouts and commercial milestones are expected in 2026, including EHA and ASCO presentations.